A Randomized Double-blind Placebo-controlled Clinical Trial of Immune Modulation by Lactococcus lactis GCWB1176 Supplementation

• 발행기관: 대한약학회
• 저자명: Hye Kim Yun-Ah Lee Yeongmin Kwon Jooyoung Kim Jae-Won Kim Se-Young Choung Sang-Wook Song Kyung-Soo Kim
• 간행물 정보: 『약학회지』제69권 제1호(2025년), 83~95쪽, 전체 13쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2025.02.28

국문 초록

Lactococcus lactis GCWB1176 (GCWB1176) is a potential probiotic supplement that can enhance human immune function. This study aimed to evaluate the function of GCWB1176 in the human immune system as a food supplement. We performed a randomized, placebo-controlled, double-blind study to ensure objective results. During the 8- week intervention period, the experimental group consumed one capsule containing 1×10¹⁰ CFU of GCWB1176 daily, whereas the control group received a placebo. Factors related to immune response, such as NK cell activity, and IFN-γ, TNF-α, IL-4, IL-10, IL-12, and WBC levels were measured. At week 4, the GCWB1176 group exhibited a significant increase in IL-12 levels and Natural killer (NK) cell activity at a 50:1 E:T (E, NK cells; T, K562 cells) ratio. However, at the endpoint week 8, no significant intergroup differences were found. The change in the intake of dietary factors such as selenium and plant fat during the experiment period apparently weakened the immunomodulatory function of GCWB1176. Nevertheless, an overall upward trend was observed in the experimental group compared with baseline. In this regard, GCWB1176 demonstrates potential for enhancing human immune function and could be developed as a dietary supplement in the future.

목차

Introduction

Methods

Results

Discussion

Conclusion

Acknowledgment

Conflict of Interest

References

키워드

Lactic acid bacteria (LAB) NK cell activity Probiotics Lactococcus lactis Whole genome sequencing